278 related articles for article (PubMed ID: 27465922)
1. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells.
Parmar MB; Arteaga Ballesteros BE; Fu T; K C RB; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
J Biomed Mater Res A; 2016 Dec; 104(12):3031-3044. PubMed ID: 27465922
[TBL] [Abstract][Full Text] [Related]
2. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
3. Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.
Plianwong S; Thapa B; Kc RB; Kucharski C; Rojanarata T; Uludağ H
Pharm Res; 2020 Feb; 37(3):46. PubMed ID: 32016611
[TBL] [Abstract][Full Text] [Related]
4. Additive Polyplexes to Undertake siRNA Therapy against CDC20 and Survivin in Breast Cancer Cells.
Parmar MB; K C RB; Löbenberg R; Uludağ H
Biomacromolecules; 2018 Nov; 19(11):4193-4206. PubMed ID: 30222931
[TBL] [Abstract][Full Text] [Related]
5. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.
Falamarzian A; Aliabadi HM; Molavi O; Seubert JM; Lai R; Uludağ H; Lavasanifar A
J Biomed Mater Res A; 2014 Sep; 102(9):3216-28. PubMed ID: 24167124
[TBL] [Abstract][Full Text] [Related]
6. siRNA therapy in cutaneous T-cell lymphoma cells using polymeric carriers.
Sahin B; Fife J; Parmar MB; Valencia-Serna J; Gul-Uludağ H; Jiang X; Weinfeld M; Lavasanifar A; Uludağ H
Biomaterials; 2014 Nov; 35(34):9382-94. PubMed ID: 25128374
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells.
Zhang C; Yuan W; Wu Y; Wan X; Gong Y
Life Sci; 2021 Feb; 266():118886. PubMed ID: 33310044
[TBL] [Abstract][Full Text] [Related]
8. Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines.
Parmar MB; Aliabadi HM; Mahdipoor P; Kucharski C; Maranchuk R; Hugh JC; Uludağ H
Front Bioeng Biotechnol; 2015; 3():14. PubMed ID: 25763370
[TBL] [Abstract][Full Text] [Related]
9. Small hydrophobe substitution on polyethylenimine for plasmid DNA delivery: Optimal substitution is critical for effective delivery.
Thapa B; Plianwong S; Remant Bahadur KC; Rutherford B; Uludağ H
Acta Biomater; 2016 Mar; 33():213-24. PubMed ID: 26802444
[TBL] [Abstract][Full Text] [Related]
10. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation.
Valencia-Serna J; Gul-Uludağ H; Mahdipoor P; Jiang X; Uludağ H
J Control Release; 2013 Dec; 172(2):495-503. PubMed ID: 23726887
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.
Montazeri Aliabadi H; Landry B; Mahdipoor P; Uludağ H
Mol Pharm; 2011 Oct; 8(5):1821-30. PubMed ID: 21838308
[TBL] [Abstract][Full Text] [Related]
12.
Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
[TBL] [Abstract][Full Text] [Related]
13. A novel tyrosine-modified low molecular weight polyethylenimine (P10Y) for efficient siRNA delivery in vitro and in vivo.
Ewe A; Przybylski S; Burkhardt J; Janke A; Appelhans D; Aigner A
J Control Release; 2016 May; 230():13-25. PubMed ID: 27061141
[TBL] [Abstract][Full Text] [Related]
14. Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy.
Aliabadi HM; Mahdipoor P; Kucharsky C; Chan N; Uludağ H
Pharm Res; 2015 Dec; 32(12):3813-26. PubMed ID: 26129766
[TBL] [Abstract][Full Text] [Related]
15. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.
Alshamsan A; Hamdy S; Samuel J; El-Kadi AO; Lavasanifar A; Uludağ H
Biomaterials; 2010 Feb; 31(6):1420-8. PubMed ID: 19913908
[TBL] [Abstract][Full Text] [Related]
16. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes.
Werth S; Urban-Klein B; Dai L; Höbel S; Grzelinski M; Bakowsky U; Czubayko F; Aigner A
J Control Release; 2006 May; 112(2):257-70. PubMed ID: 16574264
[TBL] [Abstract][Full Text] [Related]
17. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
Okamoto A; Asai T; Hirai Y; Shimizu K; Koide H; Minamino T; Oku N
Mol Pharm; 2018 Apr; 15(4):1495-1504. PubMed ID: 29502423
[TBL] [Abstract][Full Text] [Related]
18. Breathing New Life into TRAIL for Breast Cancer Therapy: Co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers.
Thapa B; Kc R; Bahniuk M; Schmitke J; Hitt M; Lavasanifar A; Kutsch O; Seol DW; Uludag H
Hum Gene Ther; 2019 Dec; 30(12):1531-1546. PubMed ID: 31547718
[TBL] [Abstract][Full Text] [Related]
19. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.
Aliabadi HM; Mahdipoor P; Uludağ H
Cancer Gene Ther; 2013 Mar; 20(3):169-77. PubMed ID: 23449477
[TBL] [Abstract][Full Text] [Related]
20. Precision combination therapy for triple negative breast cancer via biomimetic polydopamine polymer core-shell nanostructures.
Ding Y; Su S; Zhang R; Shao L; Zhang Y; Wang B; Li Y; Chen L; Yu Q; Wu Y; Nie G
Biomaterials; 2017 Jan; 113():243-252. PubMed ID: 27829203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]